Celiac plexus neurolysis for the treatment of upper abdominal cancer pain

Manoel Jacobsen Teixeira  
Eloy Rusafa Neto  
José Cláudio Marinho da Nóbrega  
Jairo Silva dos Ângelos  
Miguel San Martin  
Bernardo Assumpção de Monaco  
Erich Talamoni Fonoff

Department of Neurology, Division of Functional Neurosurgery of the Institute of Psychiatry, University of São Paulo School of Medicine, São Paulo, Brazil

Abstract: Optimal treatment of oncologic pain is a challenge to all professionals who deal with cancer and its complications. The management of upper abdominal pain is usually difficult and it is often refractory to conservative therapies. In this context, celiac plexus neurolysis (CPN) appears to be an important and indispensable tool because it alleviates pain, gives comfort to patients and is a safe procedure. In this study, the importance of CPN is reviewed by a retrospective study of 74 patients with pain due to upper abdominal cancer. Almost all cases evaluated (94.6%) had an excellent result after CPN and the majority of side effects were transitory.

Keywords: pain, celiac plexus, alcohol neurolysis, cancer

Introduction

Injections of neurolytic agents to destroy nerves and interrupt pain pathways have been used for several years.1–3 Celiac plexus neurolysis (CPN) is an ablative procedure of the celiac plexus (CP) that aims to destroy afferent pain transmitting fibers from abdominal viscera. It can be chemical, thermic or surgical, with the chemical method being limited to alcohol or phenol.

CPN is thought to be a safe and effective technique, indicated in patients with severe and intractable pain, in whom less aggressive maneuvers are ineffective or intolerable because of either poor physical condition or development of side effects.4 The World Health Organization Cancer Pain Relief Program recommends CPN for pain relief in patients with upper abdominal cancer.1–6

The noteworthy adverse effects of alcohol neurolysis include regional pain, hypotension, diarrhea, hypoxemia, and acute alcoholic intoxication,7,8 most of them transient and controllable.

The CP is situated retroperitoneal in the upper abdomen at the level of the 12th thoracic and 1st lumbar vertebrae, anterior to the crura of the diaphragm. It surrounds the abdominal aorta, celiac and superior mesenteric arteries. The plexus is comprised of a network of nerve fibers, from both sympathetic and parasympathetic systems. It receives parasympathetic fibers from the vagus nerve and contains two large ganglia that receive sympathetic fibers from the three splanchnic nerves; the right ganglion is, on average, 0.6 cm inferior to the celiac artery, whereas the left is 0.9 cm inferior.

The neural information related to visceral pain is not carried on by sympathetic nerve fibers and these pain syndromes are not dependent on sympathetic activity within the CP. The afferent fibers that bring up visceral sensory information from the upper abdomen, including the pancreas, diaphragm, liver, spleen, stomach,
bowel, proximal portion of the transverse and ascending colon, suprarenal glands, kidneys, abdominal aorta and mesentery are located within the plexus anatomical region. Impulses pass from the CP to the splanchnic nerves and enter the spinal cord from the 5th to the 9th thoracic segments.

Pain due to oncolgic infiltration of somatic territories into the abdominal wall is not conducted through celiac plexus fibers and, therefore, cannot be treated by CP ablation.

Objective
This study aims to evaluate the importance of alcohol CPN in the treatment of visceral pain due to upper abdominal cancer.

Material and methods
We retrospectively reviewed 74 patients with upper abdominal cancer and visceral pain syndromes who were submitted to percutaneous alcohol CPN from June 1989 to March 2011. Patients were selected to the procedure while having disabling pain, refractory to optimized medication and to other nonsurgical procedures; all of them had advanced oncolgic disease with life expectancy close to one year.

Celiac plexus neurolysis was first described by Ischia et al in 1919; since then, several modifications have been proposed. Our practice was based on the description of percutaneous splanchnic nerve block technique: a patient under general anesthesia is positioned in the prone position and the skin is cleaned with antiseptics. Then percutaneous fluoroscopic guided bilateral puncture is performed with a needle, 7 centimeters lateral to the midline, 45 degrees in the coronal plane, and 15 degrees cephalic to the lateral portion of the L1 vertebral body. The tip of the needle is placed under lateral-lateral and antero-posterior fluoroscopic guide, 1 to 2 centimeters anterior to the L1 vertebral body. Aspiration is first performed to ensure that vascular puncture has not occurred, then 3 mL to 5 mL of contrast agent is injected to visualize by fluoroscopy the contrast diffusion to the retrocrural and retroaortic space, anterior and lateral to the superior lumbar and inferior thoracic vertebra. The injection of 20 mL to 50 mL of absolute alcohol under fluoroscopy finalizes the procedure (Figure 1).

Response to treatment was evaluated up to 10 days after the procedure. Response was considered “bad” when pain persisted with no improvement, “good” when partial relief was achieved with improvement of quality of life, and “excellent” when pain was completely abolished.

Results
Patients were aged between 25 and 81 years old, with a mean age of 56.8 years. Thirty-nine of the 74 patients were male (52.7%), and thirty-five were female (47.3%). Seventy patients (94.6%) submitted to percutaneous alcohol CPN had an excellent response to treatment and four of them (5.4%) had a good response. The patients who had an excellent response to CPN did not need opioid medication and only stayed on lower doses of this medication for a few days in order to rule out the possibility of opioid withdrawal syndrome. The group of patients who had a good response to the CPN procedure still required some opioid and/or anti-inflammatory medication, but the analgesic medication became effective in controlling pain.

The majority of patients who underwent the procedure had uncontrolled disease and most of them experienced a progression of the disease afterwards. The CPN procedure aimed to improve the quality of life by reducing pain, and did not interfere with the disease process itself. Patients in this treatment group had a poor prognosis and low survival rate at the time of initiating the procedure. Theoretically, patients who experienced an improvement in their quality of life should respond better to treatment of their primary disease, but this fact was not really observed in this investigation.

Complications related to the procedure were: transient pain in the puncture location in 42 patients (56.7%), transitory diarrhea in 26 patients (35.1%), and hypotension responsive to volume infusion in 19 patients (25.6%), see Figure 2. No significant pleural effusion occurred in this study. One patient experienced permanent crural paraplegia (1.35%); this was the only severe complication in this trial. This patient was a 65-year-old with typical upper abdominal pain related to advanced pancreatic cancer. Around six months before
the procedure the patient underwent local radiotherapy in order to control the cancer, using the same volume of alcohol that was used in the CPN procedure guided by fluoroscopy. The neurological examination revealed anterior spinal artery syndrome with severe neurological motor deficits, with no significant sensory loss in the same territory.

Discussion

The control of visceral pain related to abdominal cancer, especially in the upper abdomen remains a challenge. Pain control is one of the most important aspects of quality of life maintenance during the treatment of these cancer patients, who often are in an advanced stage of the disease, with a short life expectancy. Unfortunately, many patients have resistance to pain medication and side effects of opioids.

The celiac plexus has a diffuse anatomical structure and is composed of more than two ganglia, therefore regardless of the technique used, CPN may have a long-lasting benefit in 70% to 90% of patients with upper abdominal cancer, appearing as a safe and cost-effective approach to treating visceral pain associated with cancer.

Despite the World Health Organization Cancer Pain Relief Program recommending CPN as the most suitable intervention in a palliative setting, this procedure still carries some misconceptions by many physicians, withholding a potential improvement in the quality of life of many terminally ill patients.

Chemical ablative procedures of a nerve or a nerve group are preferred to other mechanical modalities in order to disrupt diffuse neural networks, such as the celiac plexus. Alcohol is preferred to phenol because of the perception that it leads to more complete ablation and avoids the potential mutagenic effects of phenol.

Lillemoe et al concluded that CP alcohol neurolysis for irreversible abdominal pain from pancreatic cancer can provide significant analgesia for up to 6 months and improve survival (P < 0.0001). Wong et al in a prospective randomized trial proved this pain relief to be more effective than optimized analgesic therapy alone, however with no impact on life quality or survival.

Studies comparing percutaneous CPN with the use of opioids suggest that CPN results in a mild-to-moderate sustained reduction of pain in pancreatic cancer and an important decrease in opioid use, but does not eliminate the need for additional medication. Our study could also reproduce the good results found in the literature since all patients involved exhibited satisfactory control of pain.

Besides the fluoroscopic guided percutaneous celiac neurolysis, the computed tomography (CT) guided procedure can also be mentioned, also the intraoperative approach and the endoscopic ultrasound guided procedure (EUS). Yamamura et al state that there are no significant differences in efficacy between fluoroscopic and CT guided CPN, although the use of CT assures a correct needle tip placement.

Currently, there are few data about CPN under EUS guidance. However, the results are comparable to other conventional methods used to relieve pancreatic pain with neurolytic agent injections.

The transient adverse effects after alcohol CPN in this study were the same observed in correlated articles. Our one case of a severe complication (1.35%, crural paraplegia) was an unexpected event, nevertheless it is under the rate of 2% reported in the literature for neurolytic agent injections.

The benefits of CPN are very well known qualitatively, however quantitative studies are needed. Pain practitioners should consider the role of these blocks in adjuvant therapy for the optimal treatment of cancer pain.
Conclusion
Upper abdominal cancer causes severe pain in most patients and is often difficult to treat. Palliation of pain in these cases often requires a multidisciplinary approach, with options including oral analgesics, chemotherapy, radiotherapy, psychotherapy, nonsurgical procedures and CPN. Timely interventional cancer pain therapies complement conventional pain management by reducing the need for high-dose opioid therapy and its associated toxicity.

In a seriously impaired cancer patient scenario CPN appears as an effective procedure because it relieves visceral pain, generally with no serious adverse effects and excellent results. This positive impact on quality of life after CPN is a central aspect of this procedure among other palliative care therapeutic options.

Disclosure
The authors report no conflicts of interest in this work.

References